|
|
 |
|
Viewing report
|
|
|
|
The Global Market For Hormonal Contraceptives and Infertility Drugs, 2005-2012
Spectra Intelligence , Jan 2006, Pages: 109
Drugs in reproductive medicine are evolving into highly sophisticated products with multifunctional pharmacological properties and clinical utilities. Novel contraceptive formulations with low side-effect profiles are providing women with flexible birthcontrol and menstrual management options whilst also offering secondary indications to treat coexisting endocrinological and gynaecological disorders. Furthermore, the increasing global prevalence of infertility is driving R&D to offer novel drug solutions to improve or restore male- and female-factor infertility, optimize fertilization and embryo implantation, and reduce miscarriage.
Recent advances in administering and formulating hormone-based drugs is enabling a revolution in contraception and infertility treatments. Over the next decade, the market for hormonal contraceptives and infertility drugs is predicted to expand considerably through innovation, new and expanding markets, and high value prospects that importantly offer novel solutions to unmet needs and demands of patients who wish to modulate or enhance fertility. The current mature market for hormonal contraceptives and infertility drugs is estimated at US$7.1 billion but is forecast to increase 40% to US$9.9 billion by 2012.
This report provides a detailed analysis of the global market for hormonal contraceptives and infertility drugs highlighting strategies for product extension and reformulation, sales forecasts to 2012 for leading products, and impact of late-stage pipeline drugs on the market. Therapy area forecasting and illustrative market data and analysis is also presented to offer insights into sector performance, which may enable the reader to make key assumptions about future markets and prospects.
REPORT HIGHLIGHTS AND KEY FINDINGS
- The current market for the hormonal contraceptives and infertility drugs is valued at US$7.1 billion, which is forecast to increase 40% to US$9.9 billion by 2012
- Critical analysis of marketed hormonal contraceptives, reformulations, and infertility drugs
- Analysis of over 10 key marketed products and inclusion of 38 R&D candidates identified in preclinical to clinical stages of development
- Sales estimates (US$) to 2012 for leading products
- Strategic insights for life-cycle optimization and product development
- Commercial evaluation of leading reproductive health pharmacotherapies
- Trend analysis of industry events and activities over past 2 years
- Detailed R&D themes and clusters by therapy area
- Data generation on sector and market values between 2004 and 2012 and therapy area forecasts by 2020 (US$)
- High revenue-yielding prospects identified with projected sales estimations
- R&D pipeline positioning for novel candidates
- Market insights for product development and drug promotion
WHAT CAN I LEARN FROM THIS REPORT?
- Which contraceptives and infertility drugs are the current and potential future market leaders
- Insights into the extent of reformulations for hormonal contraceptive products
- What impact new drug approvals will have on the reproductive medicine drug market
- Which premarket drugs are identified as high-value products
- Which companies are developing hormonal contraceptives and infertility drugs
- Sales predictions to 2012 for leading contraceptives and infertility drugs
- How will newcomers affect the product positioning of market leaders
- What are niche market opportunities in reproductive medicine
- What the future outlook holds for hormonal contraceptives and infertility pharmacotherapies
- How companies are expanding the global reproductive medicine market through sophisticated reformulations and secondary indications for endocrinological and gynaecological disorders
- Which molecules and compounds are main R&D clusters in reproductive medicine
- Which of the pipeline candidates are identified as top prospects over the next decade and to 2020
Plus Many Other Insights, Observations, Assumptions, and Predictions to be Garnered…
Figure 2.2 Estimated Global Market Share for Hormonal Contraceptives and Infertility
Objectives of the Report
The objectives of this report are to provide an in-depth analysis of the global therapeutic market for hormonal contraceptives and infertility drugs. Included in this study are analyses of key therapy areas, R&D programs, and innovating companies and products. It is hoped that the reader will benefit from market forecasts, pooled knowledge of recent industrial activities and events, and from analytical discourse, which is intended to stimulate growth and create new market opportunities.
Research Methodology
The contents of this report are derived from in-depth research-based surveys of the industry and proprietary analytical assessment tools. Source material also comprises the following:
- Company information
- Personal communication
- Trade press articles
- News releases
- Internet-based research
- Library research
- Scientific periodicals
- Product information
- Market analyst data
- Public information datasets
- Conference proceedings
- Medical/pharma associations
Product samples
Samples for this product is available. Please Login/Register to download these samples.
Customers who bought this item also bought
Commercial Insight: Hormonal Contraceptives - Look Beyond Oral Contraception for a Competitive Edge
Hormonal Contraceptives Market Forecast
Stakeholder Insight: Infertility - Undifferentiated Drugs Force need to Strengthen Prescriber and Payer Relationship
World Contraceptive and Infertility Drug Markets
Strategic Perspectives 2001: Hormonal contraceptives
Commercial and Pipeline Insight: Infertility - Optimizing a market bounded by social opinion and physician preference
Contraceptives - Global Strategic Business Report
Hormonal Contraception: Market Update - Surviving the Generic Threat
Infertility Therapy Area Pipeline Report
Stakeholder Opinions: Hormonal Contraceptives - New directions in a competitive market
Women's Health Series: Is There Change Ahead for the Female Infertility Market?
Antiageing and Life Enhancement Pharmacotherapeutics: Rejuvenating Drug Markets To 2012 and Beyond
|
|
|
|
